The U.S. Food and Drug Administration (FDA) has granted Celcuity’s drug Gedatolisib Priority Review designation for its New Drug Application (NDA).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WLD’s 15% price surge follows World Network’s launch of ‘World Money’ Super App
In the coming month, you will see bitcoin prices starting with '10', or even double eleven!
Meta (META.US) data center's first high-yield bond is oversubscribed more than four times, strong demand drives premium issuance
The first junk bond issuance by the data center division of Meta Platforms attracted demand over four times the transaction size, with its enticing yields drawing in investors.
US stock index adjustments to take effect next Monday: Bloom Energy (BE.US) and Everpure (P.US) to be included in S&P 500, changes also for mid- and small-cap stocks
Bloom Energy, Illumina, and Everpure will be included in the S&P 500 index, while several other companies will be added to the S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices.
Crypto prices
More
